Showing 1 - 10 of 11
Persistent link: https://www.econbiz.de/10008648677
Persistent link: https://www.econbiz.de/10009521229
Persistent link: https://www.econbiz.de/10003784979
Persistent link: https://www.econbiz.de/10003929591
Persistent link: https://www.econbiz.de/10008648670
Persistent link: https://www.econbiz.de/10003654977
End-stage renal disease (ESRD), or kidney failure, is a debilitating, costly, and increasingly common medical condition. Little is known about how different financing approaches affect ESRD outcomes and delivery of care. This paper presents results from a comparative review of 12 countries with...
Persistent link: https://www.econbiz.de/10012465529
End-stage renal disease (ESRD), or kidney failure, is a debilitating, costly, and increasingly common medical condition. Little is known about how different financing approaches affect ESRD outcomes and delivery of care. This paper presents results from a comparative review of 12 countries with...
Persistent link: https://www.econbiz.de/10012776880
The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government...
Persistent link: https://www.econbiz.de/10012049872
Purpose – The authors focus on understanding the relationship between costs and cost sharing on medication adherence for individuals who initiated a disease-modifying therapy (DMT) for the treatment of multiple sclerosis (MS). DMTs reduce the risk of relapse and are an essential component of...
Persistent link: https://www.econbiz.de/10015381443